Referred to the House Committee on Energy and Commerce.
The bill amends the Federal Food, Drug, and Cosmetic Act to exempt “non-invasive diagnostic devices” from regulation as devices by the FDA. It defines such devices as those that do not penetrate skin or membranes, are not inserted or implanted, cause only ephemeral compression or temperature changes to in situ tissues, and do not subject tissues to ionizing radiation.
Safety oversight vs. deregulation for innovation
Relative to its intended legislative type, this bill clearly and narrowly advances a substantive change by amending the statutory definition of 'device' to exclude 'non-invasive diagnostic devices' and provides a concise statutory definition of that term.
The bill amends the Federal Food, Drug, and Cosmetic Act to exempt “non-invasive diagnostic devices” from regulation as devices by the FDA.
It defines such devices as those that do not penetrate skin or membranes, are not inserted or implanted, cause only ephemeral compression or temperature changes to in situ tissues, and do not subject tissues to ionizing radiation.
Narrow but potentially controversial deregulatory change lacking safety safeguards or compromise features, making bipartisan support uncertain.
Relative to its intended legislative type, this bill clearly and narrowly advances a substantive change by amending the statutory definition of 'device' to exclude 'non-invasive diagnostic devices' and provides a concise statutory definition of that term. However, it leaves out implementation timing, transition rules, fiscal acknowledgement, mechanisms for resolving boundary cases, and oversight or reporting provisions.
Safety oversight vs. deregulation for innovation
These are examples from the analysis, not a ranked list of the most-affected groups.
Safety oversight vs. deregulation for innovation
Likely skeptical or opposed because removing FDA device oversight reduces premarket safety and effectiveness review for diagnostic tools.
Supporters' claims about faster innovation are acknowledged, but concerns focus on patient safety, accuracy, and health equity.
Any helpful effects on access are speculative without guardrails.
Approaches the bill pragmatically: values innovation and reduced red tape but wants measurable safeguards to prevent harm.
Would look for balanced amendments like post-market surveillance, narrow scope, and clarity on medical claims and liability.
Views the bill as plausible if operational details are tightened.
Generally favorable: views exemption as smart deregulation to accelerate medical innovation and reduce federal overreach.
Sees the change as empowering entrepreneurs and consumers, lowering costs, and freeing FDA to focus on higher-risk products.
Expects market competition and liability to discipline poor products.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow but potentially controversial deregulatory change lacking safety safeguards or compromise features, making bipartisan support uncertain.
The bill has not accumulated any surfaced votes yet.
Safety oversight vs. deregulation for innovation
Narrow but potentially controversial deregulatory change lacking safety safeguards or compromise features, making bipartisan support uncert…
Relative to its intended legislative type, this bill clearly and narrowly advances a substantive change by amending the statutory definition of 'device' to exclude 'non-invasive diagnostic devices' and provides a concis…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.